Sale appoint ex-Italy lock Bortolami as head coach
Sale Sharks have appointed Marco Bortolami as head coach to work alongside director of rugby Alex Sanderson.
The ex-Italy forward replaces Paul Deacon, who left the club on Wednesday after holding the role since 2020.
Advertisement
Bortolami, 45, has been head coach of United Rugby Championship (URC) club Benetton for the past four years.
The former captain won 111 caps during a playing career which included four years in the Premiership with Gloucester.
"I'm really excited and honoured to be part of this family," Bortolami told the club's website.
"The club has been building for the last few years and to have the chance now to come and contribute is unbelievable."
Sale finished third in the Premiership, losing at Leicester Tigers in their play-off semi-final on Saturday.
It was the fourth time in the past five seasons the Sharks have finished in the top four, but they have not been champions since 2006.
Advertisement
Now Bortolami will bring his experience to the coaching team, having worked at Benetton since he retired from playing in 2016, firstly as an assistant before taking the top job.
For Sanderson, having someone of Bortolami's stature can help the club's push to take that next step.
"This is a huge coup for the club because Marco is an international-level coach," he said.
"But that's the level that our coaching needs to be at because that's the kind of team we've got here."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
China tells G7 to stop 'manipulating' China issues for its own agenda
BEIJING (Reuters) -China warned the Group of Seven advanced economies on Friday against "manipulating" issues related to the world's second-largest economy for their own agenda, after they accused Beijing of unfair business practices a year earlier. Beijing's criticism of the G7 and what it represents comes amid a surge in global trade tension between the United States and China this year, as well as within the bloc's membership. In remarks ahead of a three-day G7 summit in Canada set to start from Sunday, Lin Jian, a spokesperson of the Chinese foreign ministry, accused the group of having always upheld a Cold War mentality. The bloc should "stop interfering in other countries' internal affairs, stop undermining other countries' development, (and) stop manipulating issues related to China," Lin told a regular news conference. The G7 provokes conflicts and confrontations, said Lin, adding that such practices were "doomed to fail". In the communique after its 2024 summit in Italy that mentioned China more than 20 times, the G7 said its companies needed to be protected from China's unfair business practices. It also warned of action against Chinese financial institutions that helped Russia obtain weapons for its war in Ukraine. The participation of countries beyond the grouping, such as India and Brazil, in last year's event also irked China, which viewed the move as a bid to sow discord among countries of the Global South. New leaders will represent five of the G7's members - Britain, Canada, Germany, Japan and the United States - at next week's summit.
Yahoo
39 minutes ago
- Yahoo
Red Bull agree deal to buy Newcastle Falcons and keep Premiership club afloat
Brett Connon of Newcastle Falcons in action against Leicester Tigers during a Premiership match in May. Brett Connon of Newcastle Falcons in action against Leicester Tigers during a Premiership match in May. Photograph:Red Bull has agreed a deal to buy Newcastle Falcons which includes a commitment to keep the club in the city and will ensure the Premiership remains a 10-team competition next season. Newcastle have been for sale for over a year, with owner Semore Kurdi no longer willing to fund multimillion-pound annual losses, leading to fears they could become the fourth Premiership club to go bust in the last two years after Wasps, Worcester and London Irish. Advertisement Related: An ugly pack and backs worth paying to watch: Bath have taken us back to the 1990s | Andy Bull Such has been the concern for Newcastle's future that the other Premiership clubs agreed in principle to provide a £4m loan to enable them to take part in the competition next season, with a nine-team top-flight not thought to be commercially viable. Red Bull is understood to have reach an agreement to take over the cash-strapped club however, and take on their £39m debts. These include £14.5m in unpaid treasury loans taken out during the Covid-19 pandemic. During negotiations with the Austrian energy drinks company the prospect of moving the club to the 26,000-capacity Darlington Arena 40 miles away was discussed, but the Guardian has been told that Red Bull's takeover plan involves Newcastle staying at Kingston Park, which has been their home for the past 35 years. Advertisement Red Bull's decision to stay in Newcastle is likely to be popular with the club's longsuffering fans, who did not see them win a single match last season and only two this as Steve Diamond's side finished bottom of the Premiership on both occasions. The company's vision for the club is understood to be based on using their brands and marketing expertise to gain support from younger people in the city, with several campaigns planned to appeal to Newcastle's student population. Given the company's footballing connections Red Bull is also expected to seek a close working relationship with Newcastle United. The club's outgoing sporting director Paul Mitchell previously worked at RB Leipzig. Newcastle will be Red Bull's first rugby purchase, but the club aligns with it's purchase model of snapping up underperforming sports teams with a business plan of transforming them into global brands. The company paid Ford just $1 to buy the failing Formula One team, Jaguar Racing, in 2004 and have successfully transformed them into giants of the sport, with Red Bull Racing winning eight world drivers' championships and six constructors' titles in the last 15 years. In addition to football clubs, RB Leipzig, Red Bull Salzburg and the New York Red Bulls, they also own 9.9% of Leeds United and are heavily involved in motor sport and winter sports. Advertisement Attracting a new owner such as Red Bull is also a coup for Premiership Rugby, who are seeing much-needed signs of growth for the sport. Viewing figures for Premiership matches on TNT Sport are up 10% on last season before Saturday's final between Bath and Leicester, with the increase 47% when the game directly follows a Premier League match. In another significant boost TNT Sport last month agreed a new five-year deal giving it exclusive live rights for every Premiership match until 2031. Red Bull and Newcastle declined to comment on the deal.
Yahoo
44 minutes ago
- Yahoo
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /CNW/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon (SCB) compared to an everolimus-eluting stent (EES) in treating de-novo coronary vessels. TRANSFORM II (Sirolimus-Coated Balloon Versus Drug-Eluting Stent in Native Coronary Vessels) is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare in Milano, Italy, and has now achieved its target enrollment of >1,820 patients. The final patient was enrolled on 6th June 2025, marking a major milestone for the trial. Led by Study Chairman Prof. Bernardo Cortese (University Hospitals Harrington Heart & Vascular Institute, Cleveland, USA) and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloon and has enrolled patients from 52 centers across Europe, Asia and South America. Key features of the TRANSFORM II trial include: Comparative Arms: MagicTouch SCB vs. Everolimus-Eluting Stent (EES) Patient Population: 1,832 patients with de-novo lesions in coronary arteries (vessel diameter >2.0 mm to ≤3.5 mm; lesion length ≤50 mm) Primary Endpoint: Target Lesion Failure at 12 months, non-inferiority design Follow-Up: Patients will be monitored for up to 60 months (5 years) Sub-Study: Optical Coherence Tomography (OCT) imaging in 70 patients at 9 months to assess angiographic outcomes Prof. Bernardo Cortese, Study Chairman of TRANSFORM II, commented: "After 3 and a half years we were able to complete the enrollment in TRANSFORM II trial, a study that involved 52 centers across 3 continents, and this is amazing. The effort put by our Team in Fondazione RIC and each Investigator of the study led to a quite fast enrollment in such a big, ambitious study. Our goal is to advance the adoption of DCB in the coronary space, testing this sirolimus DCB with the most studied and used DES, in a daily patient population. Along with the guidance of the recently published DCB ARC guidelines, we are paving the route for the modern angioplasty era!". Coronary vessels of this size (which account for roughly 80% of patients undergoing percutaneous coronary interventions) present unique treatment challenges. Currently, interventional cardiologists must often choose a permanent implant namely a drug-eluting stent — effectively "caging" a small vessel — which may compromise long-term outcomes. The head-to-head comparison of MagicTouch SCB against a current standard of care (the EES family of drug-eluting stents) in TRANSFORM II is poised to provide critical evidence for an alternative approach. This trial has the potential to reshape treatment practices by establishing drug-coated balloons as the next viable option for patients with coronary artery disease. Drug-coated balloon technology has long been viewed as a promising solution for small, de-novo coronary lesions, and sirolimus is a viable alternative to the first generation of DCB eluting paclitaxel. Data from this large-scale RCT are expected to support a paradigm shift towards broader use of drug-coated balloons. Implanting a drug-eluting stent in a tiny artery is far from ideal for both patients and physicians, so a rigorous study validating the use of SCB was needed. TRANSFORM II is set to fulfill that need, with initial 12-month outcomes anticipated to shed light on the long-term benefits of avoiding permanent implants in coronary vessels. Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, commented: "The completion of patient enrollment in TRANSFORM II is a significant milestone in our mission to bring innovative drug-delivery technologies to the forefront of interventional cardiology. We are proud to scientifically support one of the largest global randomized trials evaluating sirolimus-coated balloon technology. This achievement reflects our commitment to clinical excellence, scientific rigor, and ultimately, better outcomes for patients around the world." About MagicTouch SCB The MagicTouch SCB, developed by Concept Medical Inc., utilizes proprietary Nanoluté technology to deliver sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall. The device has received CE Mark approval in Europe alongwith Breakthrough Device Designation & IDE Approval from the U.S. FDA for the treatment of small coronary vessels and in-stent restenosis with ongoing clinical trials. About Concept Medical Inc. Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of Sirolimus-Coated Balloons (SCB) – the world's first and most utilized SCB technology – well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over a million patients globally, setting a new standard for vascular therapy. For more information, please visit Photo: View original content to download multimedia: SOURCE Concept Medical Inc. View original content to download multimedia:
